{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:54:32Z","timestamp":1788216872679,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00284-023-03304-1","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T16:01:41Z","timestamp":1682611301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection"],"prefix":"10.1007","volume":"80","author":[{"given":"Anupriya","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra Goud","family":"Vaggu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrushna","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"3304_CR1","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/PNAS.2003138117\/SUPPL_FILE\/PNAS.2003138117.SD01.XLSX","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang J, Wan Y, Luo C et al (2020) Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA 117:11727\u201311734. https:\/\/doi.org\/10.1073\/PNAS.2003138117\/SUPPL_FILE\/PNAS.2003138117.SD01.XLSX","journal-title":"Proc Natl Acad Sci USA"},{"key":"3304_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00018-020-03611-x","volume":"78","author":"J Wu","year":"2021","unstructured":"Wu J, Deng W, Li S, Yang X (2021) Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci 78:531\u2013544","journal-title":"Cell Mol Life Sci"},{"key":"3304_CR3","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1042\/CS20201268","volume":"134","author":"FJ Warner","year":"2020","unstructured":"Warner FJ, Rajapaksha H, Shackel N, Herath CB (2020) ACE2: from protection of liver disease to propagation of COVID-19. Clin Sci 134:3137\u20133158. https:\/\/doi.org\/10.1042\/CS20201268","journal-title":"Clin Sci"},{"key":"3304_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/gutjnl-2019-318512","volume":"69","author":"M Garg","year":"2020","unstructured":"Garg M, Royce SG, Tikellis C et al (2020) Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut 69:841\u2013854. https:\/\/doi.org\/10.1136\/gutjnl-2019-318512","journal-title":"Gut"},{"key":"3304_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fimmu.2015.00551","volume":"6","author":"I Loddo","year":"2015","unstructured":"Loddo I, Romano C (2015) Inflammatory bowel disease: Genetics, epigenetics, and pathogenesis. Front Immunol 6:551","journal-title":"Front Immunol"},{"key":"3304_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fimmu.2012.00107","volume":"3","author":"DC Rubin","year":"2012","unstructured":"Rubin DC, Shaker A, Levin MS (2012) Chronic intestinal inflammation: Inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 3:107","journal-title":"Front Immunol"},{"key":"3304_CR7","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn\u2019s disease. Lancet 389:1741\u20131755. https:\/\/doi.org\/10.1016\/S0140-6736(16)31711-1","journal-title":"Lancet"},{"key":"3304_CR8","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/ibd.21925","volume":"18","author":"JE Baars","year":"2012","unstructured":"Baars JE, Nuij VJAA, Oldenburg B et al (2012) Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 18:1634\u20131640. https:\/\/doi.org\/10.1002\/ibd.21925","journal-title":"Inflamm Bowel Dis"},{"key":"3304_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000367859","volume":"32","author":"EJ De Groof","year":"2014","unstructured":"De Groof EJ, Carbonnel F, Buskens CJ, Bemelman WA (2014) Abdominal abscess in Crohn\u2019s disease: multidisciplinary management. Dig Dis 32:103\u2013109. https:\/\/doi.org\/10.1159\/000367859","journal-title":"Dig Dis"},{"key":"3304_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1053\/j.gastro.2015.08.001","volume":"149","author":"DPB McGovern","year":"2015","unstructured":"McGovern DPB, Kugathasan S, Cho JH (2015) Genetics of inflammatory bowel diseases. Gastroenterology 149:1163-1176.e2. https:\/\/doi.org\/10.1053\/j.gastro.2015.08.001","journal-title":"Gastroenterology"},{"key":"3304_CR11","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1111\/j.1572-0241.2007.01527.x","volume":"102","author":"J Van Limbergen","year":"2007","unstructured":"Van Limbergen J, Russell RK, Nimmo ER, Satsangi J (2007) The genetics of inflammatory bowel disease. Am J Gastroenterol 102:2820\u20132831","journal-title":"Am J Gastroenterol"},{"key":"3304_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1126\/science.1209791","volume":"334","author":"S Vaishnava","year":"2011","unstructured":"Vaishnava S, Yamamoto M, Severson KM et al (2011) The antibacterial lectin RegIII\u03b3 promotes the spatial segregation of microbiota and host in the intestine. Science (80-) 334:255\u2013258. https:\/\/doi.org\/10.1126\/science.1209791","journal-title":"Science (80-)"},{"key":"3304_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/MCG.0b013e3182688e73","volume":"47","author":"D Boltin","year":"2013","unstructured":"Boltin D, Perets TT, Vilkin A, Niv Y (2013) Mucin function in inflammatory bowel disease: an update. J Clin Gastroenterol 47:106\u2013111","journal-title":"J Clin Gastroenterol"},{"key":"3304_CR14","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1097\/MIB.0000000000000080","volume":"20","author":"IO Gordon","year":"2014","unstructured":"Gordon IO, Agrawal N, Goldblum JR et al (2014) Fibrosis in ulcerative colitis: Mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis 20:2198\u20132206. https:\/\/doi.org\/10.1097\/MIB.0000000000000080","journal-title":"Inflamm Bowel Dis"},{"key":"3304_CR15","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1001\/jama.242.11.1177","volume":"242","author":"JB Kirsner","year":"1979","unstructured":"Kirsner JB (1979) The local and systemic complications of inflammatory bowel disease. JAMA J Am Med Assoc 242:1177\u20131183. https:\/\/doi.org\/10.1001\/jama.242.11.1177","journal-title":"JAMA J Am Med Assoc"},{"key":"3304_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S0016-5085(03)00271-3","volume":"124","author":"L Dubuquoy","year":"2003","unstructured":"Dubuquoy L, Jansson \u00c5E, Deeb S et al (2003) Impaired expression of peroxisome proliferator-activated receptor \u03b3in ulcerative colitis. Gastroenterology 124:1265\u20131276. https:\/\/doi.org\/10.1016\/S0016-5085(03)00271-3","journal-title":"Gastroenterology"},{"key":"3304_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/0091270007301623","volume":"47","author":"BE Sands","year":"2007","unstructured":"Sands BE, Kaplan GG (2007) The role of TNF\u03b1 in ulcerative colitis. J Clin Pharmacol 47:930\u2013941","journal-title":"J Clin Pharmacol"},{"key":"3304_CR18","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0\/ATTACHMENT\/6407BFD5-7E96-4D9B-9C6E-A1B6C2C06FBC\/MMC1.PDF","volume":"380","author":"I Ordas","year":"2012","unstructured":"Ordas I, Eckmann L, Talamini M et al (2012) Ulcerative colitis. Lancet 380:1606\u20131619. https:\/\/doi.org\/10.1016\/S0140-6736(12)60150-0\/ATTACHMENT\/6407BFD5-7E96-4D9B-9C6E-A1B6C2C06FBC\/MMC1.PDF","journal-title":"Lancet"},{"key":"3304_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","volume":"12","author":"SS Seyedian","year":"2019","unstructured":"Seyedian SS, Nokhostin F, Malamir MD (2019) A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 12:113\u2013122","journal-title":"J Med Life"},{"key":"3304_CR20","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3748\/wjg.v23.i9.1541","volume":"23","author":"DS Politis","year":"2017","unstructured":"Politis DS, Katsanos KH, Tsianos EV, Christodoulou DK (2017) Pseudopolyps in inflammatory bowel diseases: Have we learned enough? World J Gastroenterol 23:1541\u20131551","journal-title":"World J Gastroenterol"},{"key":"3304_CR21","first-page":"76","volume":"31","author":"T Wedel","year":"2015","unstructured":"Wedel T, Barrenschee M, Lange C et al (2015) Morphologic basis for developing diverticular disease, diverticulitis, and diverticular bleeding. Visz Gastrointest Med Surg 31:76\u201382","journal-title":"Visz Gastrointest Med Surg"},{"key":"3304_CR22","volume-title":"Acute Diverticulitis","author":"CD Linzay","year":"2022","unstructured":"Linzay CD, Pandit S (2022) Acute Diverticulitis. StatPearls, St. Petersburg"},{"key":"3304_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/1940-6207.CAPR-16-0124","volume":"9","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sandborn WJ, Gupta S (2016) Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management. Cancer Prev Res 9:887\u2013894","journal-title":"Cancer Prev Res"},{"key":"3304_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/0016-5085(94)90167-8","volume":"107","author":"SE Kern","year":"1994","unstructured":"Kern SE, Redston M, Seymour AB et al (1994) Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology 107:420\u2013428. https:\/\/doi.org\/10.1016\/0016-5085(94)90167-8","journal-title":"Gastroenterology"},{"key":"3304_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.7326\/M15-0039","volume":"163","author":"S Friis","year":"2015","unstructured":"Friis S, Riis AH, Erichsen R et al (2015) Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann Intern Med 163:347\u2013355. https:\/\/doi.org\/10.7326\/M15-0039","journal-title":"Ann Intern Med"},{"key":"3304_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00005-009-0031-z","volume":"57","author":"A Szkaradkiewicz","year":"2009","unstructured":"Szkaradkiewicz A, Marciniak R, Chudzicka-Struga\u0142a I et al (2009) Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz) 57:291\u2013294. https:\/\/doi.org\/10.1007\/s00005-009-0031-z","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"3304_CR27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s10620-005-3032-8","volume":"50","author":"PR Holt","year":"2005","unstructured":"Holt PR, Katz S, Kirshoff R (2005) Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50:2191\u20132193. https:\/\/doi.org\/10.1007\/s10620-005-3032-8","journal-title":"Dig Dis Sci"},{"key":"3304_CR28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cgh.2006.03.020","volume":"4","author":"M Cruz-Correa","year":"2006","unstructured":"Cruz-Correa M, Shoskes DA, Sanchez P et al (2006) Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4:1035\u20131038. https:\/\/doi.org\/10.1016\/j.cgh.2006.03.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3304_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1155\/2012\/256294","volume":"2012","author":"C Tikellis","year":"2012","unstructured":"Tikellis C, Thomas MC (2012) Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012:8","journal-title":"Int J Pept"},{"key":"3304_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3390\/ijms17070797","volume":"17","author":"N Mu\u00f1oz-Durango","year":"2016","unstructured":"Mu\u00f1oz-Durango N, Fuentes CA, Castillo AE et al (2016) Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: Molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. Int J Mol Sci 17:797","journal-title":"Int J Mol Sci"},{"key":"3304_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150861","author":"MA Khajah","year":"2016","unstructured":"Khajah MA, Fateel MM, Ananthalakshmi KV, Luqmani YA (2016) Anti-inflammatory action of angiotensin 1\u20137 in experimental colitis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0150861","journal-title":"PLoS ONE"},{"key":"3304_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1365-2036.2011.04971.x","volume":"35","author":"M Garg","year":"2012","unstructured":"Garg M, Angus PW, Burrell LM et al (2012) Review article: The pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. Aliment Pharmacol Ther 35:414\u2013428","journal-title":"Aliment Pharmacol Ther"},{"key":"3304_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1515\/BC.2001.013","volume":"382","author":"K Bhoola","year":"2001","unstructured":"Bhoola K, Ramsaroop R, Plendl J et al (2001) Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 382:77\u201390. https:\/\/doi.org\/10.1515\/BC.2001.013","journal-title":"Biol Chem"},{"key":"3304_CR34","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1097\/MIB.0000000000000858","volume":"22","author":"DK McDaniel","year":"2016","unstructured":"McDaniel DK, Eden K, Ringel VM, Allen IC (2016) Emerging roles for noncanonical NF-kB signaling in the modulation of inflammatory bowel disease pathobiology. Inflamm Bowel Dis 22:2265\u20132279","journal-title":"Inflamm Bowel Dis"},{"key":"3304_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bph.12159","volume":"169","author":"E Sim\u00f5es","year":"2013","unstructured":"Sim\u00f5es E, Silva AC, Silveira KD, Ferreira AJ, Teixeira MM (2013) ACE2, angiotensin-(1\u20137) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 169:477\u2013492","journal-title":"Br J Pharmacol"},{"key":"3304_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13069-015-0023-z","volume":"8","author":"AM Murphy","year":"2015","unstructured":"Murphy AM, Wong AL, Bezuhly M (2015) Modulation of angiotensin II signaling in the prevention of fibrosis. Fibrogenes Tissue Repair 8:1\u20137","journal-title":"Fibrogenes Tissue Repair"},{"key":"3304_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/206020a0","volume":"206","author":"S Hannoodee","year":"2022","unstructured":"Hannoodee S, Nasuruddin DN (2022) Acute inflammatory response. Nature 206:20. https:\/\/doi.org\/10.1038\/206020a0","journal-title":"Nature"},{"key":"3304_CR38","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1128\/jvi.02472-07","volume":"82","author":"K Narayanan","year":"2008","unstructured":"Narayanan K, Huang C, Lokugamage K et al (2008) Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol 82:4471\u20134479. https:\/\/doi.org\/10.1128\/jvi.02472-07","journal-title":"J Virol"},{"key":"3304_CR39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","volume":"53","author":"R Zhou","year":"2020","unstructured":"Zhou R, To KKW, Wong YC et al (2020) Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 53:864-877.e5. https:\/\/doi.org\/10.1016\/j.immuni.2020.07.026","journal-title":"Immunity"},{"key":"3304_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235458","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhou X, Qiu Y et al (2020) Clinical characteristics of 82 cases of death from COVID-19. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0235458","journal-title":"PLoS ONE"},{"key":"3304_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay MZ, Poh CM, R\u00e9nia L et al (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20:363\u2013374","journal-title":"Nat Rev Immunol"},{"key":"3304_CR42","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/J.CELL.2021.03.005","volume":"184","author":"JL Schneider","year":"2021","unstructured":"Schneider JL, Rowe JH, Garcia-de-Alba C et al (2021) The aging lung: Physiology, disease, and immunity. Cell 184:1990\u20132019. https:\/\/doi.org\/10.1016\/J.CELL.2021.03.005","journal-title":"Cell"},{"key":"3304_CR43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y et al (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46:586\u2013590. https:\/\/doi.org\/10.1007\/s00134-020-05985-9","journal-title":"Intensive Care Med"},{"key":"3304_CR44","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1053\/j.gastro.2020.10.041","volume":"160","author":"AA Potdar","year":"2021","unstructured":"Potdar AA, Dube S, Naito T et al (2021) Altered intestinal ACE2 levels are associated with inflammation, severe disease, and response to anti-cytokine therapy in inflammatory bowel disease. Gastroenterology 160:809\u2013822. https:\/\/doi.org\/10.1053\/j.gastro.2020.10.041","journal-title":"Gastroenterology"},{"key":"3304_CR45","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1053\/j.gastro.2020.04.051","volume":"159","author":"M Garg","year":"2020","unstructured":"Garg M, Christensen B, Lubel JS (2020) Gastrointestinal ACE2, COVID-19 and IBD: opportunity in the Face of Tragedy? Gastroenterology 159:1623\u20131624","journal-title":"Gastroenterology"},{"key":"3304_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","volume":"76","author":"P Verdecchia","year":"2020","unstructured":"Verdecchia P, Cavallini C, Spanevello A, Angeli F (2020) The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 76:14\u201320","journal-title":"Eur J Intern Med"},{"key":"3304_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7150\/ijbs.23489","volume":"14","author":"CI Lin","year":"2018","unstructured":"Lin CI, Tsai CH, Sun YL et al (2018) Instillation of particulate matter 2.5 induced acute lung injury and attenuated the injury recovery in ACE2 knockout mice. Int J Biol Sci 14:253\u2013265. https:\/\/doi.org\/10.7150\/ijbs.23489","journal-title":"Int J Biol Sci"},{"key":"3304_CR48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S et al (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436:112\u2013116. https:\/\/doi.org\/10.1038\/nature03712","journal-title":"Nature"},{"key":"3304_CR49","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033\u20131034","journal-title":"Lancet"},{"key":"3304_CR50","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.3389\/fimmu.2021.732690","volume":"12","author":"K Kuba","year":"2021","unstructured":"Kuba K, Yamaguchi T, Penninger JM (2021) Angiotensin-converting enzyme 2 (ACE2) in the pathogenesis of ARDS in COVID-19. Front Immunol 12:5468","journal-title":"Front Immunol"},{"key":"3304_CR51","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.3389\/FIMMU.2022.1001951\/BIBTEX","volume":"13","author":"MP Lennol","year":"2022","unstructured":"Lennol MP, Garc\u00eda-Ayll\u00f3n MS, Esteban M et al (2022) Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy. Front Immunol 13:6177. https:\/\/doi.org\/10.3389\/FIMMU.2022.1001951\/BIBTEX","journal-title":"Front Immunol"},{"key":"3304_CR52","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil V, Kwon H, Prado P et al (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181:905-913.e7. https:\/\/doi.org\/10.1016\/j.cell.2020.04.004","journal-title":"Cell"},{"key":"3304_CR53","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(20)30418-5","volume":"8","author":"A Zoufaly","year":"2020","unstructured":"Zoufaly A, Poglitsch M, Aberle JH et al (2020) Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med 8:1154\u20131158. https:\/\/doi.org\/10.1016\/S2213-2600(20)30418-5","journal-title":"Lancet Respir Med"},{"key":"3304_CR54","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013426","author":"V Monteil","year":"2021","unstructured":"Monteil V, Dyczynski M, Lauschke VM et al (2021) Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Mol Med. https:\/\/doi.org\/10.15252\/emmm.202013426","journal-title":"EMBO Mol Med"},{"key":"3304_CR55","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3390\/ijms18102021","volume":"18","author":"A Manzo","year":"2017","unstructured":"Manzo A, Montanino A, Carillio G et al (2017) Angiogenesis inhibitors in NSCLC. Int J Mol Sci 18:2021","journal-title":"Int J Mol Sci"},{"key":"3304_CR56","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.08.002","author":"LM Ellis","year":"2006","unstructured":"Ellis LM (2006) Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. https:\/\/doi.org\/10.1053\/j.seminoncol.2006.08.002","journal-title":"Semin Oncol"},{"key":"3304_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21085-8","author":"J Pang","year":"2021","unstructured":"Pang J, Xu F, Aondio G et al (2021) Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-021-21085-8","journal-title":"Nat Commun"},{"key":"3304_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-00217-2","author":"PG Wang","year":"2020","unstructured":"Wang PG, Tang DJ, Hua Z et al (2020) Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation. Cell Discov. https:\/\/doi.org\/10.1038\/s41421-020-00217-2","journal-title":"Cell Discov"},{"key":"3304_CR59","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","volume":"21","author":"A Carrato Mena","year":"2010","unstructured":"Carrato Mena A, Grande Pulido E, Guill\u00e9n-Ponce C (2010) Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 21:S3","journal-title":"Anticancer Drugs"},{"key":"3304_CR60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00280-019-03876-5","volume":"84","author":"T Hirai","year":"2019","unstructured":"Hirai T, Shuji Y, Takiyama M et al (2019) Renin\u2013angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis. Cancer Chemother Pharmacol 84:195\u2013202. https:\/\/doi.org\/10.1007\/s00280-019-03876-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"3304_CR61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/0975-7406.80764","volume":"3","author":"P Wal","year":"2011","unstructured":"Wal P, Wal A, Rai A, Dixit A (2011) Aliskiren: an orally active renin inhibitor. J Pharm Bioallied Sci 3:189\u2013193","journal-title":"J Pharm Bioallied Sci"},{"issue":"1","key":"3304_CR62","doi-asserted-by":"publisher","first-page":"27552","DOI":"10.1038\/srep27552","volume":"6","author":"Y Shi","year":"2016","unstructured":"Shi Y, Liu T, He L, Dougherty U, Chen L, Adhikari S et al (2016) Activation of the renin-angiotensin system promotes colitis development. Sci Rep 6(1):27552. https:\/\/doi.org\/10.1038\/srep27552","journal-title":"Sci Rep"},{"key":"3304_CR63","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1517\/14656566.2011.585460","volume":"12","author":"L Ghiadoni","year":"2011","unstructured":"Ghiadoni L (2011) Perindopril for the treatment of hypertension. Expert Opin Pharmacother 12:1633\u20131642. https:\/\/doi.org\/10.1517\/14656566.2011.585460","journal-title":"Expert Opin Pharmacother"},{"key":"3304_CR64","doi-asserted-by":"publisher","first-page":"236","DOI":"10.17179\/excli2021-3370","volume":"20","author":"F Asgharzadeh","year":"2021","unstructured":"Asgharzadeh F, Yaghoubi A, Nazari SE, Hashemzadeh A, Hasanian SM, Avan A, Javandoost A, Ferns GA, Soleimanpour S, Khazaei M (2021) The beneficial effect of combination therapy with sulfasalazine and valsartan in the treatment of ulcerative colitis. EXCLI J 20:236\u2013247. https:\/\/doi.org\/10.17179\/excli2021-3370","journal-title":"EXCLI J"},{"key":"3304_CR65","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.regpep.2007.10.004","volume":"146","author":"OI Santiago","year":"2008","unstructured":"Santiago OI, Rivera E, Ferder L, Appleyard CB (2008) An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis. Regul Pept 146:250\u2013259. https:\/\/doi.org\/10.1016\/j.regpep.2007.10.004","journal-title":"Regul Pept"},{"key":"3304_CR66","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s10620-011-1651-9","volume":"56","author":"M Okawada","year":"2011","unstructured":"Okawada M, Koga H, Larsen SD et al (2011) Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis. Dig Dis Sci 56:2553\u20132565. https:\/\/doi.org\/10.1007\/s10620-011-1651-9","journal-title":"Dig Dis Sci"},{"key":"3304_CR67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1155\/2012\/628268","volume":"26","author":"D Wengrower","year":"2012","unstructured":"Wengrower D, Zanninelli G, Latella G et al (2012) Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol 26:33\u201339. https:\/\/doi.org\/10.1155\/2012\/628268","journal-title":"Can J Gastroenterol"},{"key":"3304_CR68","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/bcpt.13624","volume":"129","author":"H Salmenkari","year":"2021","unstructured":"Salmenkari H, Korpela R, Vapaatalo H (2021) Renin\u2013angiotensin system in intestinal inflammation\u2014Angiotensin inhibitors to treat inflammatory bowel diseases? Basic Clin Pharmacol Toxicol 129:161\u2013172","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3304_CR69","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1517\/14656566.5.7.1589","volume":"5","author":"J \u00d6stergren","year":"2004","unstructured":"\u00d6stergren J (2004) Candesartan for the treatment of hypertension and heart failure. Expert Opin Pharmacother 5:1589\u20131597. https:\/\/doi.org\/10.1517\/14656566.5.7.1589","journal-title":"Expert Opin Pharmacother"},{"key":"3304_CR70","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1517\/14656566.7.14.1945","volume":"7","author":"RS McKelvie","year":"2006","unstructured":"McKelvie RS (2006) Candesartan for the management of heart failure: More than an alternative. Expert Opin Pharmacother 7:1945\u20131956. https:\/\/doi.org\/10.1517\/14656566.7.14.1945","journal-title":"Expert Opin Pharmacother"},{"key":"3304_CR71","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/j.1476-5381.2012.01905.x","volume":"166","author":"AZ El-Hashim","year":"2012","unstructured":"El-Hashim AZ, Renno WM, Raghupathy R et al (2012) Angiotensin-(1\u20137) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1\/2- and NF-kB-dependent pathways. Br J Pharmacol 166:1964\u20131976. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01905.x","journal-title":"Br J Pharmacol"},{"key":"3304_CR72","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/jrr\/rraa142","volume":"62","author":"O Mungunsukh","year":"2021","unstructured":"Mungunsukh O, George J, McCart EA et al (2021) Captopril reduces lung inflammation and accelerated senescence in response to thoracic radiation in mice. J Radiat Res 62:236\u2013248. https:\/\/doi.org\/10.1093\/jrr\/rraa142","journal-title":"J Radiat Res"},{"key":"3304_CR73","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.tips.2015.03.001","volume":"36","author":"DG Passos-Silva","year":"2015","unstructured":"Passos-Silva DG, Brandan E, Santos RAS (2015) Angiotensins as therapeutic targets beyond heart disease. Trends Pharmacol Sci 36:310\u2013320","journal-title":"Trends Pharmacol Sci"},{"key":"3304_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21218068","volume":"21","author":"AS Lee","year":"2020","unstructured":"Lee AS, Hur HJ, Sung MJ (2020) The effect of artemisinin on inflammation-associated lymphangiogenesis in experimental acute colitis. Int J Mol Sci 21:1\u201312. https:\/\/doi.org\/10.3390\/ijms21218068","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3304_CR75","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.crohns.2013.12.012","volume":"8","author":"F Algieri","year":"2014","unstructured":"Algieri F, Rodriguez-Nogales A, Garrido-Mesa N, Zorrilla P, Burkard N, Pischel I et al (2014) Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis. J Crohn\u2019s Colitis 8(8):775\u2013788. https:\/\/doi.org\/10.1016\/j.crohns.2013.12.012","journal-title":"J Crohn's Colitis"},{"key":"3304_CR76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40495-021-00259-4","volume":"7","author":"R Rolta","year":"2021","unstructured":"Rolta R, Salaria D, Sharma PP et al (2021) Phytocompounds of rheum emodi, thymus serpyllum, and artemisia annua inhibit spike protein of SARS-CoV-2 Binding to ACE2 receptor: in silico approach. Curr Pharmacol Rep 7:135\u2013149","journal-title":"Curr Pharmacol Rep"},{"key":"3304_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/METABO13020243","author":"LF Laurindo","year":"2023","unstructured":"Laurindo LF, de Maio MC, Minniti G et al (2023) Effects of medicinal plants and phytochemicals in Nrf2 pathways during inflammatory bowel diseases and related colorectal cancer: a comprehensive review. Metabolites. https:\/\/doi.org\/10.3390\/METABO13020243","journal-title":"Metabolites"},{"key":"3304_CR78","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1161\/HYPERTENSIONAHA.120.15782","volume":"76","author":"C Wu","year":"2020","unstructured":"Wu C, Ye D, Mullick AE et al (2020) Effects of Renin-Angiotensin Inhibition on ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Protease Serine 2) Expression: Insights Into COVID-19. Hypertension 76:E29\u2013E30","journal-title":"Hypertension"},{"key":"3304_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00708","author":"SHP Oliveira","year":"2019","unstructured":"Oliveira SHP, Brito VGB, Frasnelli SCT et al (2019) Aliskiren Attenuates the Inflammatory Response and Wound Healing Process in Diabetic Mice With Periodontal Disease. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.00708","journal-title":"Front Pharmacol"},{"key":"3304_CR80","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10787-018-0545-2","volume":"27","author":"X Wang","year":"2019","unstructured":"Wang X, Chen X, Huang W et al (2019) Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF-\u03baB pathways in B and T cells. Inflammopharmacology 27:487\u2013502. https:\/\/doi.org\/10.1007\/s10787-018-0545-2","journal-title":"Inflammopharmacology"},{"key":"3304_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244708","author":"O Bolotova","year":"2020","unstructured":"Bolotova O, Yoo J, Chaudhri I et al (2020) Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: a feasibility study. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0244708","journal-title":"PLoS ONE"},{"key":"3304_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2478\/jtim-2021-0011","volume":"9","author":"J Gong","year":"2021","unstructured":"Gong J, Sun Y, Xie L (2021) ACEI\/ARB drug therapy in COVID-19 patients: Yes or no. J Transl Intern Med 9:8\u201311","journal-title":"J Transl Intern Med"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-023-03304-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-023-03304-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-023-03304-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T02:01:49Z","timestamp":1684720909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-023-03304-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3304"],"URL":"https:\/\/doi.org\/10.1007\/s00284-023-03304-1","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"16 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that they have no known competing financial interests or personal ties that may have influenced the work presented in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"194"}}